Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals Chief Operating Officer Barton Russell reported automatic sales of company common stock to cover taxes on vested restricted stock units. On January 21, 2026, he sold 2,315 shares at a weighted average price of $1.806 per share, and on January 22, 2026, he sold an additional 462 shares at $1.84 per share. These transactions were executed as "sell to cover" trades under a Rule 10b5-1 trading plan that he adopted on August 30, 2024, specifically to satisfy tax withholding obligations related to RSU vesting.
Following these transactions, Russell directly held 205,092 shares of Acumen Pharmaceuticals common stock.
Acumen Pharmaceuticals, Inc. (ABOS) shareholder Derek Meisner filed a notice of proposed sale on Form 144 covering 5,633 shares of common stock. The shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.
The planned sale is to be executed through Merrill Lynch on or about 01/23/2026 on the NASDAQ, with an indicated aggregate market value of $10,492.83. The filing notes that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding at the time referenced.
The document also lists prior sales by Meisner over the past three months, including multiple common stock transactions in January 2026 with stated gross proceeds for each sale.
Acumen Pharmaceuticals insider Derek Meisner has filed a notice to sell additional common stock of ABOS. The filing states an intention to sell 1,054 shares of common stock through Merrill Lynch on the NASDAQ around 01/22/2026. These 1,054 shares were acquired on 01/17/2026 via the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
The notice also lists prior sales of Acumen Pharmaceuticals common stock by Meisner over the past three months. These include multiple transactions between 01/05/2026 and 01/21/2026, with individual sales such as 4,000 shares for $7,838.00, 36,911 shares for $67,244.23, and other trades in the low‑thousands of shares. The filing reports 60,573,425 shares of common stock outstanding.
Acumen Pharmaceuticals insider plans a small stock sale. A Form 144 notice reports an intended sale of 895 shares of Acumen Pharmaceuticals common stock through Merrill Lynch on or about 01/22/2026, with an aggregate market value of $1,628.90. The shares trade on the NASDAQ, where 60,573,425 common shares were outstanding at the time of the notice.
The 895 shares to be sold came from the vesting of a restricted stock unit award on 01/17/2026, granted under the company’s equity compensation plan. The filer, identified as Eric Siemers, also sold 4,000, 6,834, and 2,331 shares of Acumen common stock on 01/05/2026, 01/06/2026, and 01/21/2026, for gross proceeds of $7,834.80, $13,442.82, and $4,203.85, respectively.
Acumen Pharmaceuticals insider Russell Barton has filed a notice of proposed sale under Rule 144 covering 462 shares of common stock. The shares are to be sold through Merrill Lynch on 01/22/2026 on the NASDAQ market, with an aggregate market value of $850.08. Shares outstanding were 60,573,425, which is a baseline figure for the company’s equity.
The 462 shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. The filing also lists several prior sales of Acumen common stock by Barton over the past three months, including 4,000 shares sold on 01/05/2026 for gross proceeds of
Acumen Pharmaceuticals insider plans additional stock sale. A person identified as Matt Zuga filed a notice to sell 1,687 shares of Acumen Pharmaceuticals, Inc. common stock through Merrill Lynch on NASDAQ, with an aggregate market value of $3,137.82. These shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with payment recorded on the same date.
The filing also lists prior sales of Acumen common stock by the same seller over the past three months, including 4,000 shares sold on 01/05/2026, 5,100 shares on 01/06/2026, 5,805 shares on 01/07/2026, 6,888 shares on 01/08/2026, and 2,473 shares on 01/21/2026, each with stated gross proceeds. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the company’s operations.
Acumen Pharmaceuticals, Inc. shareholder Daniel OConnell filed a notice of proposed sale of common stock under Rule 144. The filing covers the planned sale of 2,689 shares of common stock through Merrill Lynch, with an aggregate market value of $5,065.60 and 60,573,425 shares outstanding. The planned sale is expected around 01/22/2026 on the NASDAQ exchange.
The 2,689 shares to be sold were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan, with the same date listed for payment. The notice also lists prior sales of Acumen Pharmaceuticals common stock by Daniel OConnell over the past three months, including multiple transactions between 01/05/2026 and 01/21/2026 with disclosed share amounts and gross proceeds for each sale.
Acumen Pharmaceuticals Chief Executive Officer and director Daniel Joseph O’Connell reported new equity awards in the form of restricted stock units and stock options. On January 20, 2026, he received 299,800 shares of Common Stock as a restricted stock unit (RSU) award at a price of $0, increasing his directly held Common Stock to 893,310 shares after the transaction. Each RSU represents the right to receive one share of Acumen’s Common Stock and will vest in three equal annual installments starting one year after the grant date, contingent on his continued service.
On the same date, O’Connell was also granted an employee stock option covering 450,000 shares of Common Stock at an exercise price of $1.86 per share. These options were awarded at no upfront cost and will vest in 48 equal monthly installments so that they are fully vested on the fourth anniversary of the grant date, again subject to his continuous service. Following this grant, he holds 450,000 stock options directly.
Acumen Pharmaceuticals reported that its CFO and Chief Business Officer, Matt Zuga, received new equity awards. On
On the same date, he also received an Employee Stock Option to buy 148,700 shares of Common Stock at an exercise price of
Acumen Pharmaceuticals’ Chief Legal Officer Derek M. Meisner reported new equity awards in the company. On January 16, 2026, he received 99,133 shares of Common Stock as a restricted stock unit (RSU) award at a price of $0 per share, bringing his directly owned Common Stock to 182,933 shares. Each RSU represents a right to receive one share of Common Stock and will vest in three equal annual installments starting one year after the grant date, as long as he continues in service.
He also received an employee stock option to buy 148,700 shares of Common Stock at an exercise price of $1.89 per share, with no cost reported for the grant itself. These options vest in 48 equal monthly installments and are fully vested on the fourth anniversary of the grant date, subject to his continuous service, and expire on January 16, 2036.